Compare JD.Com Inc (JD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Merck & Co., Inc. — how do they compare? JD.Com Inc trades at $27.11 (market cap $36.62B), while Merck & Co., Inc. trades at $146.31 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 9.6× JD.Com Inc's market cap, and JD.Com Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Merck & Co., Inc. for 98 Days on average.
| JD | MRK | |
|---|---|---|
Market Cap | $36.62B | $351.28B |
Volume | 6,571,477 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $156.43 |
52-Week Low | $25.19 | $82.49 |
Typical Hold Time | 85 Days | 98 Days |
Enterprise Value | $19.26B | $398.04B |
Dividend Yield | 3.72% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $27.17, up 0.5% on the day, with strong analyst support (69.6% buy ratings) and a consensus price target of $35.86 suggesting 32% upside. Recent quarterly earnings have consistently beaten expectations, though revenue growth has slowed to 0.3% year-over-year for 2026. The stock appears fundamentally undervalued with a P/E of 17.9 and P/S of 0.2, while technical indicators show a mixed but slightly bullish bias with key support at $27.
JD offers significant valuation upside potential given its low multiples and strong cash position, but faces headwinds from slowing revenue growth and regulatory scrutiny of its European expansion. The company's robust balance sheet with $234 billion cash provides stability, though competitive pressures in Chinese e-commerce and macroeconomic concerns remain key risks for investors.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
